18F-FDG PET/CT in diagnosis of renal disease combined with tumor
10.13929/j.1003-3289.201807025
- Author:
Lei KANG
1
Author Information
1. Department of Nuclear Medicine, Peking University First Hospital
- Publication Type:Journal Article
- Keywords:
Fluorodeoxyglucose F 18;
Neoplasms;
Positron-emission tomography;
Renal disease
- From:
Chinese Journal of Medical Imaging Technology
2019;35(3):404-407
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the value of 18F-FDG PET/CT in diagnosing renal disease combined with tumor. Methods 18F-FDG PET/CT data of 146 patients with renal disease were retrospectively analyzed. The maximum standardized uptake value (SUVmax) was measured. The results of pathology were taken as the final diagnostic criteria to evaluate the efficacy of 18F-FDG PET/CT in diagnosing tumor in patients with renal disease. Results Totally 29 cases were found combined with tumor, including 19 cases with renal damage secondary to tumors and 10 cases as nephropathy coincident with tumors. PET/CT found 72 cases of 18F-FDG uptake increased (SUVmax=5.25±3.94). 18F-FDG PET/CT diagnosed tumors in 34 cases, including 29 cases were then confirmed and 5 misdiagnosed, the diagnostic sensitivity and specificity of PET/CT was 100% (29/29) and 88.37% (38/43), respectively. SUVmax of lesions of secondary nephropathy by tumor was 5.95±3.02, SUVmax of lesions of nephropathy coincident with tumor was 6.58±5.29, there was no significant difference (P>0.05). Conclusion 18F-FDG PET/CT may be used to screen tumors in patients with renal disease, but it has limited value to explore the relationship between renal disease and tumor.
